Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. |
| |
| Authors: | M S Piver J Malfetano T R Baker R E Hempling |
| |
| Affiliation: | Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263. |
| |
| Abstract: | Thirty-two stage IC or stage I grade 3 patients with invasive ovarian adenocarcinoma were treated with 6 months of adjuvant cisplatin-based chemotherapy. With a median follow-up of 60.5 months, there have been three (9%) recurrences. The 5-year progression-free survival was 90.5% and the 5-year survival was 93.3%. |
| |
| Keywords: | |
|
|
